

Molecular Pathology/Molecular Diagnostics/ Genetic Testing

Guideline Number: MPG210.29
Approval Date: April 10, 2024

[↪ Terms and Conditions](#)

Table of Contents	Page
Policy Summary	1
Applicable Codes	3
References	3
Guideline History/Revision Information	32
Purpose	32
Terms and Conditions	32

Related Medicare Advantage Policy Guidelines

- [Biomarkers in Cardiovascular Risk Assessment](#)
- [Blood Product Molecular Antigen Typing](#)
- [Clinical Diagnostic Laboratory Services](#)
- [Genetic Testing for Cardiovascular Disease](#)
- [Genetic Testing for Hereditary Cancer](#)
- [Molecular Pathology/Genetic Testing Reported with Unlisted Codes](#)
- [Pharmacogenomics Testing](#)
- [Tier 2 Molecular Pathology Procedures](#)
- [Urogenital/Anogenital \(UG/AG\) Panels](#)

Related Medicare Advantage Reimbursement Policies

- [Clinical Laboratory Improvement Amendments \(CLIA\) ID Requirement Policy, Professional](#)
- [Laboratory Services Policy, Professional](#)
- [Molecular Pathology Policy, Professional and Facility](#)

Related Medicare Advantage Coverage Summary

- [Molecular Pathology/Molecular Diagnostics/Genetic Testing](#)

Policy Summary

[↪ See Purpose](#)

Overview

A molecular diagnostic test (MDT) is any test that involves the detection or identification of nucleic acid(s) deoxyribonucleic acid/ribonucleic acid (DNA/RNA), proteins, chromosomes, enzymes, cancer chemotherapy sensitivity and/or other metabolite(s). The test may or may not include multiple components. A MDT may consist of a single mutation analysis/identification, and/or may or may not rely upon an algorithm or other form of data evaluation/derivation.

A laboratory developed test (LDT) is any test developed by a laboratory developed without Food and Drug Administration (FDA) approval or clearance.

Applicable Tests/Assays

In addition to the MDT definition, this policy applies to all tests that meet at least one of the following descriptions:

- Non-FDA approved/cleared laboratory developed tests (LDT).
- Modified FDA-approved/cleared kits/tests/assays.
- Tests/assays billed with more than one code from a HIPAA compliant code set to identify the service, including combinations of method-based, serology-based, and anatomic pathology codes.

Medicare expects laboratory providers to follow test indications published by the developer.

Next Generation Sequencing (NGS)

Clinical laboratory diagnostic tests can include tests that, for example, predict the risk associated with one or more genetic variations. In addition, in vitro companion diagnostic laboratory tests provide a report of test results of genetic variations and are essential for the safe and effective use of a corresponding therapeutic product. Next Generation Sequencing (NGS) is one technique that can measure one or more genetic variations as a laboratory diagnostic test, such as when used as a companion in vitro diagnostic test.

- National Coverage Determination (NCD) 90.2 outlines coverage of applicable diagnostic lab tests using NGS for somatic (acquired) and germline (inherited) cancer.
- Local Coverage Determinations (LCDs) may determine coverage of diagnostic lab tests using NGS for RNA sequencing and protein analysis.

Guidelines

Molecular pathology procedures have broad clinical and research applications. The following examples of applications may not be relevant to a Medicare member or may not meet a Medicare benefit category and/or reasonable and necessary threshold for coverage. Such examples include genetic testing and genetic counseling (when applicable) for:

- Disease risk;
- Carrier screening;
- Hereditary cancer syndromes;
- Gene expression profiling for certain cancers;
- Prenatal diagnostic testing;
- Diagnosis and monitoring non-cancer indications; and
- Several pharmacogenomic applications.

Based on the Centers for Medicare & Medicaid Services (CMS), this policy addresses the circumstances under which the item or service is reasonable and necessary. For laboratory services, a service may be reasonable and necessary if the service is safe and effective; and appropriate, including the duration and frequency that is considered appropriate for the item or service, in terms of whether it is furnished in accordance with accepted standards of medical practice for the diagnosis of the patient's condition; furnished in a setting appropriate to the patient's medical needs and condition; ordered and furnished by qualified personnel; one that meets, but does not exceed, the patient's medical need; and is at least as beneficial as an existing and available medically appropriate alternative.

Many applications of the molecular pathology procedures are not covered services given lack of benefit category (preventive service) and/or failure to reach the reasonable and necessary threshold for coverage (based on quality of clinical evidence and strength of recommendation). Furthermore, payment of claims in the past (based on stacking codes) or in the future (based on the new code series) is not a statement of coverage since the service was not audited for compliance with program requirements and documentation supporting the reasonable and necessary testing for the member. Certain tests and procedures may be subject to prepayment medical review (records requested) and paid claims must be supportable, if selected, for post payment audit. Tests for diseases or conditions that manifest severe signs or symptoms in newborns and in early childhood or that result in early death (e.g., Canavan disease) could be subject to automatic denials since these tests are not usually relevant to a Medicare member.

Documentation Guidelines

Documentation must be adequate to verify that coverage guidelines listed above have been met. Thus, the medical record must contain documentation that the testing is expected to influence treatment of the condition toward which the testing is directed. The laboratory or billing provider must have on file the physician requisition which sets forth the diagnosis or condition that warrants the test(s).

Examples of documentation requirements of the ordering physician/non-physician practitioner (NPP) include, but are not limited to, history and physical or exam findings that support the decision making, problems/diagnoses, relevant data (e.g., lab testing, imaging results).

Documentation requirements of the performing laboratory (when requested) include, but are not limited to, lab accreditation, test requisition, test record/procedures, reports (preliminary and final), and quality control record.

Documentation requirements for lab developed tests/protocols (when requested) include diagnostic test/assay, lab/manufacture, names of comparable assays/services (if relevant), description of assay, analytical validity evidence, clinical validity evidence, and clinical utility.

When the documentation does not meet the criteria for the service rendered or the documentation does not establish the medical necessity for the services, such services will be denied as not reasonable and necessary.

Nationally Non-Covered Indications

Compliance with the provisions in this policy is subject to monitoring by post payment data analysis and subsequent medical review. Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states "...no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis and treatment of illness or injury...". Furthermore, it has been longstanding CMS policy that **"tests that are performed in the absence of signs, symptoms, complaints, or personal history of disease or injury are not covered unless explicitly authorized by statute"**.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Codes/HCPCS Codes

[Molecular Pathology/Molecular Diagnostics/Genetic Testing: CPT/HCPCS Code List](#)

CPT® is a registered trademark of the American Medical Association

Diagnosis Codes

Refer to [Molecular Pathology/Molecular Diagnostics/Genetic Testing: Diagnosis Code List](#) for diagnosis codes for CPT codes 0005U, 0018U, 0026U, 0027U, 0045U, 0047U, 0080U, 0089U, 0090U, 0155U, 0245U, 0287U, 0288U, 81170, 81175, 81176, 81272, 81279, 81309, 81314, 81338, 81339, 81345, 81347, 81519, 81529, 81542, 81545, 81546, 81552, 81554, 88120, and 88121.

Non-Covered Diagnosis Code

[Non-Covered Diagnosis Codes List](#)

This list contains diagnosis codes that are **never covered when given as the primary reason for the test**. If a code from this section is given as the reason for the test and you know or have reason to believe the service may not be covered, call UnitedHealthcare to issue an Integrated Denial Notice (IDN) to the member and you. The IDN informs the member of their liability for the non-covered service or item and appeal rights. You must make sure the member has received the IDN prior to rendering or referring for non-covered services or items in order to collect payment.

References

CMS National Coverage Determinations (NCDs)

Refer to [NCD 90.2 Next Generation Sequencing \(NGS\)](#) for additional information on CPT codes 0022U, 0037U, 0111U, 0172U, 0239U, 0242U, and 0397U.

CMS Local Coverage Determinations (LCDs) and Articles

LCD	Article	Contractor	Medicare Part A	Medicare Part B
General Molecular Diagnostic Tests (may also include the specific tests/genes listed below)				
L36021 Molecular Diagnostic Tests (MDT)	A56973 Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT)	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A57526 Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT)	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A57527 Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT)	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY

LCD	Article	Contractor	Medicare Part A	Medicare Part B
General Molecular Diagnostic Tests (may also include the specific tests/genes listed below)				
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A56853 Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT)	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A57772 Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT)	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L34519 Molecular Pathology Procedures	A57451 Billing and Coding: Molecular Pathology Procedures	First Coast	FL, PR, VI	FL, PR, VI
	A58918 Billing and Coding: Molecular Pathology and Genetic Testing			
L35396 Biomarkers for Oncology	A52986 Billing and Coding: Biomarkers for Oncology	Novitas	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
L35062 Biomarkers Overview	A56541 Billing and Coding: Biomarkers Overview	Novitas	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
	A58917 Billing and Coding: Molecular Pathology and Genetic Testing	Novitas	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
L35000 Molecular Pathology Procedures	A56199 Billing and Coding: Molecular Pathology Procedures	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI
Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia AML				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A55716 Billing and Coding: MoIDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A55711 Billing and Coding: MoIDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A55712 Billing and Coding: MoIDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A55695 Billing and Coding: MoIDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55738 Billing and Coding: MoIDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Afirma™ Assay by Veracyte				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54185 Billing and Coding: MoIDX: Afirma™ Assay by Veracyte Update	CGS	KY, OH	KY, OH

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Afirma™ Assay by Veracyte				
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54356 Billing and Coding: MoIDX: Afirma™ Assay by Veracyte	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54358 Billing and Coding: MoIDX: Afirma™ Assay by Veracyte	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53098 Billing and Coding: MoIDX: Afirma™ Assay by Veracyte Update	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55139 Billing and Coding: MoIDX: Afirma™ Assay by Veracyte Update	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Algorithm Definition				
N/A	A58677 MoIDX: Algorithm definition as a component of a laboratory test	CGS	KY, OH	KY, OH
N/A	A58673 MoIDX: Algorithm definition as a component of a laboratory test	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A58674 MoIDX: Algorithm definition as a component of a laboratory test	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A58650 MoIDX: Algorithm definition as a component of a laboratory test	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
N/A	A58689 MoIDX: Algorithm definition as a component of a laboratory test	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Allograft Rejection for Solid Organ				
L38582 MoIDX: Molecular Testing for Solid Organ Allograft Rejection	A58061 Billing and Coding: MoIDX: Molecular Testing for Solid Organ Allograft Rejection	CGS	KY, OH	KY, OH
L38629 MoIDX: Molecular Testing for Solid Organ Allograft Rejection	A58168 Billing and Coding: MoIDX: Molecular Testing for Solid Organ Allograft Rejection	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38671 MoIDX: Molecular Testing for Solid Organ Allograft Rejection	A58170 Billing and Coding: MoIDX: Molecular Testing for Solid Organ Allograft Rejection	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38568 MoIDX: Molecular Testing for Solid Organ Allograft Rejection	A58019 Billing and Coding: MoIDX: Molecular Testing for Solid Organ Allograft Rejection	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38680 MoIDX: Molecular Testing for Solid Organ Allograft Rejection	A58207 Billing and Coding: MoIDX: Molecular Testing for Solid Organ Allograft Rejection	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
AlloMap				
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54364 Billing and Coding: MoIDX: AlloMap Retired 06/09/2023	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54366 Billing and Coding: MoIDX: AlloMap Retired 06/09/2023	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY

LCD	Article	Contractor	Medicare Part A	Medicare Part B
APC and MUTYH Gene Testing				
L36910 MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	A56828 Billing and Coding: MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	CGS	KY, OH	KY, OH
L36882 MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	A57352 Billing and Coding: MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36884 MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	A57353 Billing and Coding: MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L36827 MoIDX: APC and MUTYH Gene Testing Retired 07/03/2022	A56824 Billing and Coding: MoIDX: APC and MUTYH Gene Testing Retired 07/03/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37224 MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	A56901 Billing and Coding: MoIDX: APC and MUTYH Gene Testing Retired 08/20/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Aspartoacyclase 2 Deficiency ASPA Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54253 Billing and Coding: MoIDX: Aspartoacyclase 2 Deficiency (ASPA) Testing	CGS	KY, OH	KY, OH
N/A	A55088 Billing and Coding: MoIDX: Aspartoacyclase 2 Deficiency (ASPA) Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55089 Billing and Coding: MoIDX: Aspartoacyclase 2 Deficiency (ASPA) Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53602 Billing and Coding: MoIDX: Aspartoacyclase 2 Deficiency (ASPA) Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55142 Billing and Coding: MoIDX: Aspartoacyclase 2 Deficiency (ASPA) Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
ATP7B Gene Tests				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54254 Billing and Coding: MoIDX: ATP7B Gene Tests	CGS	KY, OH	KY, OH
N/A	A55097 Billing and Coding: MoIDX: ATP7B Gene Tests	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55098 Billing and Coding: MoIDX: ATP7B Gene Tests	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53550 Billing and Coding: MoIDX: ATP7B Gene Tests	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55143 Billing and Coding: MoIDX: ATP7B Gene Tests	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
BCKDHB Gene Test				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54255 Billing and Coding: MoIDX: BCKDHB Gene Test	CGS	KY, OH	KY, OH

LCD	Article	Contractor	Medicare Part A	Medicare Part B
BCKDHB Gene Test				
N/A	A55099 Billing and Coding: MoIDX: BCKDHB Gene Test	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55100 Billing and Coding: MoIDX: BCKDHB Gene Test	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53600 Billing and Coding: MoIDX: BCKDHB Gene Test	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55145 Billing and Coding: MoIDX: BCKDHB Gene Test	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
BCR - ABL				
L36117 MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	A56999 Billing and Coding: MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	CGS	KY, OH	KY, OH
	A54686 Billing and Coding: MoIDX: BCR - ABL			
L36180 MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	A57421 Billing and Coding: MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
	A55595 Billing and Coding: MoIDX: BCR-ABL			
L36186 MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	A57422 Billing and Coding: MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
	A55600 Billing and Coding: MoIDX: BCR-ABL			
L36044 MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	A56959 Billing and Coding: MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
	A53531 Billing and Coding: MoIDX: BCR-ABL			
L36815 MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	A57570 Billing and Coding: MoIDX: Genetic Testing for BCR - ABL Negative Myeloproliferative Disease	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
	A55233 Billing and Coding: MoIdx: BCR-ABL			
BDX-XL2				
L37134 BDX-XL2 Retired 05/01/2022	A56947 Billing and Coding: BDX-XL2 Retired 05/01/2022	CGS	KY, OH	KY, OH
L37054 BDX-XL2	A57356 Billing and Coding: BDX-XL2	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37062 BDX-XL2	A57357 Billing and Coding: BDX-XL2	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY

LCD	Article	Contractor	Medicare Part A	Medicare Part B
BDX-XL2				
L37031 BDX-XL2	A56929 Billing and Coding: BDX-XL2	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37216 BDX-XL2	A57558 Billing and Coding: BDX-XL2	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
bioTheranostics Cancer TYPE ID® Update				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54188 Billing and Coding: MoIDX: bioTheranostics Cancer TYPE ID®	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54386 Billing and Coding: MoIDX: bioTheranostics Cancer TYPE ID® Update	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54388 Billing and Coding: MoIDX: bioTheranostics Cancer TYPE ID® Update	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53101 Billing and Coding: MoIDX: bioTheranostics Cancer TYPE ID® Update	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55147 Billing and Coding: MoIDX: bioTheranostics Cancer TYPE ID® Update	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Bladder/Urothelial Tumor Markers				
L36975 Bladder/Urothelial Tumor Markers	A56471 Billing and Coding: Bladder/Urothelial Tumor Markers	CGS	KY, OH	KY, OH
L36678 Lab: Bladder/Urothelial Tumor Markers	A55028 Billing and Coding: Lab: Bladder/Urothelial Tumor Markers	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36680 Lab: Bladder/Urothelial Tumor Markers	A55029 Billing and Coding: Lab: Bladder/Urothelial Tumor Markers	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L33420 Lab: Bladder/Urothelial Tumor Markers	A53095 Billing and Coding: Lab: Bladder/Urothelial Tumor Markers	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
BLM Gene Analysis				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54256 Billing and Coding: MoIDX: BLM Gene Analysis	CGS	KY, OH	KY, OH
N/A	A55113 Billing and Coding: MoIDX: BLM Gene Analysis	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55114 Billing and Coding: MoIDX: BLM Gene Analysis	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53540 Billing and Coding: MoIDX: BLM Gene Analysis	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55148 Billing and Coding: MoIDX: BLM Gene Analysis	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
BRAF Tests FDA - Approved				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54191 Billing and Coding: MoIDX: FDA - Approved BRAF Tests	CGS	KY, OH	KY, OH

LCD	Article	Contractor	Medicare Part A	Medicare Part B
BRAF Tests FDA - Approved				
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54418 Billing and Coding: MoIDX: FDA - Approved BRAF Tests	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54420 Billing and Coding: MoIDX: FDA - Approved BRAF Tests	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A54018 Billing and Coding: MoIDX: FDA - Approved BRAF Tests	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55161 Billing and Coding: MoIDX: FDA - Approved BRAF Tests	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
BRCA1 and BRCA2 Genetic Testing				
L36499 BRCA1 and BRCA2 Genetic Testing	A57449 Billing and Coding: BRCA1 and BRCA2 Genetic Testing	First Coast	FL, PR, VI	FL, PR, VI
L36456 MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	A56971 Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	CGS	KY, OH	KY, OH
L36161 MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	A57354 Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36163 MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	A57355 Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L36082 MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 07/03/2022	A56854 Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 07/03/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36813 MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	A57771 Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing Retired 08/20/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L36715 BRCA1 and BRCA2 Genetic Testing	A56542 Billing and Coding: BRCA1 and BRCA2 Genetic Testing	Novitas	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
Breast Cancer Assay: Prosigna®				
L36425 MoIDX: Breast Cancer Assay: Prosigna®	A56989 Billing and Coding: MoIDX: Breast Cancer Assay: Prosigna®	CGS	KY, OH	KY, OH
L36380 MoIDX: Breast Cancer Assay: Prosigna®	A57363 Billing and Coding: MoIDX: Breast Cancer Assay: Prosigna®	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36386 MoIDX: Breast Cancer Assay: Prosigna®	A57364 Billing and Coding: MoIDX: Breast Cancer Assay: Prosigna®	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Breast Cancer Assay: Prosigna®				
L36125 MoIDX: Breast Cancer Assay: Prosigna®	A56949 Billing and Coding: MoIDX: Breast Cancer Assay: Prosigna®	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36811 MoIDX: Breast Cancer Assay: Prosigna®	A57560 Billing and Coding: MoIDX: Breast Cancer Assay: Prosigna®	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Breast Cancer Index® BCI Gene Expression Test				
L37832 MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	A56884 Billing and Coding: MoIDX: Breast Cancer Index™ (BCI) Gene Expression Test	CGS	KY, OH	KY, OH
L37822 MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	A57773 Billing and Coding: MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37824 MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	A57774 Billing and Coding: MoIDX: Breast Cancer Index™ (BCI) Gene Expression Test	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37794 MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	A56875 Billing and Coding: MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37913 MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	A56335 Billing and Coding: MoIDX: Breast Cancer Index® (BCI) Gene Expression Test	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
ConfirmMDx Epigenetic Molecular Assay				
L36006 MoIDX: ConfirmMDx Epigenetic Molecular Assay	A57031 Billing and Coding: MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 01/01/2024	CGS	KY, OH	KY, OH
L36327 MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 08/08/2022	A57605 Billing and Coding: MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 08/08/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36329 MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 08/08/2022	A57606 Billing and Coding: MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 08/08/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35632 MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 07/03/2022	A56955 Billing and Coding: MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 07/03/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37005 MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 08/20/2022	A57561 Billing and Coding: MoIDX: ConfirmMDx Epigenetic Molecular Assay Retired 08/20/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Corus® CAD Assay				
L37787 MoIDX: Corus® CAD Assay Retired 05/01/2022	A56950 Billing and Coding: MoIDX: Corus® CAD Assay Retired 05/01/2022	CGS	KY, OH	KY, OH
L37673 MoIDX: Corus® CAD Assay Retired 02/15/2022	A57415 Billing and Coding: MoIDX: Corus® CAD Assay Retired 02/15/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Corus® CAD Assay				
L37675 MoIDX: Corus® CAD Assay Retired 02/15/2022	A57416 Billing and Coding: MoIDX: Corus® CAD Assay Retired 02/15/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37612 MoIDX: Corus® CAD Assay Retired 02/15/2022	A56930 Billing and Coding: MoIDX: Corus® CAD Assay Retired 02/15/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37770 MoIDX: Corus® CAD Assay Retired 10/17/2022	A57562 Billing and Coding: MoIDX: Corus® CAD Assay Retired 10/17/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Cxbladder				
L35396 Biomarkers for Oncology	A52986 Billing and Coding: Biomarkers for Oncology A58529 Response to Comments: Biomarkers for Oncology Effective 12/13/2020 - 11/07/2022	Novitas	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
Decision Dx-UM Uveal Melanoma				
L37130 MoIDX: DecisionDx-UM (Uveal Melanoma)	A56981 Billing and Coding: MoIDX: DecisionDx-UM (Uveal Melanoma)	CGS	KY, OH	KY, OH
L37070 MoIDX: DecisionDx-UM (Uveal Melanoma)	A57621 Billing and Coding: MoIDX: DecisionDx-UM (Uveal Melanoma)	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37072 MoIDX: DecisionDx-UM (Uveal Melanoma)	A57622 Billing and Coding: MoIDX: DecisionDx-UM (Uveal Melanoma)	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37033 MoIDX: DecisionDx-UM (Uveal Melanoma)	A56906 Billing and Coding: MoIDX: DecisionDx-UM (Uveal Melanoma)	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37210 MoIDX: Decision Dx-UM (Uveal Melanoma)	A57566 Billing and Coding: MoIDX: Decision Dx-UM (Uveal Melanoma)	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
EGFR Tests FDA-Approved				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54192 Billing and Coding: MoIDX: FDA - Approved EGFR Tests	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54422 Billing and Coding: MoIDX: FDA - Approved EGFR Tests	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54424 Billing and Coding: MoIDX: FDA - Approved EGFR Tests	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A54021 Billing and Coding: MoIDX: FDA - Approved EGFR Tests	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55193 Billing and Coding: MoIDX: FDA - Approved EGFR Tests	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
EndoPredict® Breast Cancer Gene Expression Test				
L37356 MoIDX: EndoPredict Breast Cancer Gene Expression Test	A56997 Billing and Coding: MoIDX: EndoPredict Breast Cancer Gene Expression Test	CGS	KY, OH	KY, OH
L37295 MoIDX: EndoPredict® Breast Cancer Gene Expression Test	A57607 Billing and Coding: MoIDX: EndoPredict® Breast Cancer Gene Expression Test	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37311 MoIDX: EndoPredict® Breast Cancer Gene Expression Test	A57608 Billing and Coding: MoIDX: EndoPredict® Breast Cancer Gene Expression Test	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37264 MoIDX: EndoPredict Breast Cancer Gene Expression Test	A56963 Billing and Coding: MoIDX: EndoPredict Breast Cancer Gene Expression Test	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37663 MoIDX: EndoPredict® Breast Cancer Gene Expression Test	A57567 Billing and Coding: MoIDX: EndoPredict® Breast Cancer Gene Expression Test	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test				
L37905 MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	A56985 Billing and Coding: MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	CGS	KY, OH	KY, OH
L37887 MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	A57419 Billing and Coding: MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37891 MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	A57420 Billing and Coding: MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37857 MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	A56898 Billing and Coding: MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37919 MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	A57568 Billing and Coding: MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
FANCC Genetic Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54263 Billing and Coding: MoIDX: FANCC Genetic Testing	CGS	KY, OH	KY, OH
N/A	A55183 Billing and Coding: MoIDX: FANCC Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55184 Billing and Coding: MoIDX: FANCC Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53628 Billing and Coding: MoIDX: FANCC Genetic Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55160 Billing and Coding: MoIDX: FANCC Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Fragile X				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54264 Billing and Coding: MoIDX: Fragile X	CGS	KY, OH	KY, OH

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Fragile X				
N/A	A55241 Billing and Coding: MoIDX: Fragile X	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55242 Billing and Coding: MoIDX: Fragile X	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53638 Billing and Coding: MoIDX: Fragile X	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55163 Billing and Coding: MoIDX: Fragile X	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
GBA Genetic Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54265 Billing and Coding: MoIDX: GBA Genetic Testing	CGS	KY, OH	KY, OH
N/A	A55243 Billing and Coding: MoIDX: GBA Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55244 Billing and Coding: MoIDX: GBA Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53542 Billing and Coding: MoIDX: GBA Genetic Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55164 Billing and Coding: MoIDX: GBA Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
HBB Gene Tests				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54267 Billing and Coding: MoIDX: HBB Gene Tests	CGS	KY, OH	KY, OH
N/A	A55253 Billing and Coding: MoIDX: HBB Gene Tests	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55254 Billing and Coding: MoIDX: HBB Gene Tests	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53493 Billing and Coding: MoIDX: HBB Gene Tests	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55166 Billing and Coding: MoIDX: HBB Gene Tests	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
HEXA Gene Analysis				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54268 Billing and Coding: MoIDX: HEXA Gene Analysis	CGS	KY, OH	KY, OH
N/A	A55255 Billing and Coding: MoIDX: HEXA Gene Analysis	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55256 Billing and Coding: MoIDX: HEXA Gene Analysis	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53598 Billing and Coding: MoIDX: HEXA Gene Analysis	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55168 Billing and Coding: MoIDX: HEXA Gene Analysis	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Histochemical Stains and Immunohistochemical Stains				
L36234 Special Histochemical Stains & Immunohistochemical Stains Retired 12/11/2022	A57708 Billing and Coding: Special Histochemical Stains & Immunohistochemical Stains Retired 12/11/2022	First Coast	FL, PR, VI	FL, PR, VI
L35986 Special Histochemical Stains and Immunohistochemical Stains	A59292 Billing and Coding: Lab: Immunohistochemistry (IHC) Indications for Breast Pathology	CGS	KY, OH	KY, OH
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54271 Billing and Coding: MoIDX: Immunohistochemistry (IHC) Indications for Breast Pathology			
L36351 Lab: Special Histochemical Stains and Immunohistochemical Stains	A57611 Billing and Coding: Lab: Special Histochemical Stains and Immunohistochemical Stains A57523 Billing and Coding: MoIDX: Immunohistochemistry (IHC) Indications for Breast Pathology	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36353 Lab: Special Histochemical Stains and Immunohistochemical Stains	A57614 Billing and Coding: Lab: Special Histochemical Stains and Immunohistochemical Stains A57797 Billing and Coding: MoIDX: Immunohistochemistry (IHC) Indications for Breast Pathology	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35922 Lab: Special Histochemical Stains and Immunohistochemical Stains	A56838 Billing and Coding: Lab: Special Histochemical Stains and Immunohistochemical Stains A53704 Billing and Coding: Lab: Immunohistochemistry (IHC) Indications for Breast Pathology	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36805 Lab: Special Histochemical Stains and Immunohistochemical Stains	A57733 Billing and Coding: Lab: Special Histochemical Stains and Immunohistochemical Stains A55136 Billing and Coding: MoIDX: Immunohistochemistry (IHC) Indications for Breast Pathology	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Hypercoagulability/Thrombophilia Factor V Leiden, Factor II Prothrombin, and MTHFR				
L35984 MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	A56980 Billing and Coding: MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	CGS	KY, OH	KY, OH
L36155 MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	A57423 Billing and Coding: MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36159 MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	A57424 Billing and Coding: MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L36089 MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	A56899 Billing and Coding: MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36400 MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	A57571 Billing and Coding: MoIDX: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
IKBKAP Genetic Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54270 Billing and Coding: MoIDX: IKBKAP Genetic Testing	CGS	KY, OH	KY, OH
N/A	A55612 Billing and Coding: MoIDX: IKBKAP Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55613 Billing and Coding: MoIDX: IKBKAP Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53596 Billing and Coding: MoIDX: IKBKAP Genetic Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55170 Billing and Coding: MoIDX: IKBKAP Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer				
L37903 MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	A56982 Billing and Coding: MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	CGS	KY, OH	KY, OH

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer				
L37897 MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	A57664 Billing and Coding: MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37899 MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	A57665 Billing and Coding: MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37870 MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	A56924 Billing and Coding: MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37921 MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	A56333 Billing and Coding: MoIDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
4Kscore® Assay				
L36979 4Kscore® Assay Retired 05/01/2022	A56944 Billing and Coding: 4Kscore® Assay Retired 05/01/2022	CGS	KY, OH	KY, OH
L37120 MoIDX: 4Kscore Assay Retired 06/11/2022	A57336 Billing and Coding: 4Kscore® Assay Retired 06/12/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37122 MoIDX: 4Kscore Assay Retired 06/12/2022	A57337 Billing and Coding: 4Kscore® Assay Retired 06/12/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L36763 4Kscore® Assay	A56932 Billing and Coding: 4Kscore® Assay	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37013 4Kscore® Assay Retired 10/17/2022	A57556 Billing and Coding: 4Kscore® Assay Retired 10/17/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L37798 4Kscore Test Algorithm	A56287 Billing and Coding: 4Kscore Test Algorithm	First Coast	FL, PR, VI	FL, PR, VI
L37792 4Kscore Test Algorithm Retired 03/01/2024	A56653 Billing and Coding: 4Kscore Test Algorithm	Novitas	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX
L37733 Biomarker Testing for Prostate Cancer Diagnosis Retired 03/01/2024	A56609 Billing and Coding: Biomarker Testing for Prostate Cancer Diagnosis	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI
KRAS Tests FDA-Approved				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54688 Billing and Coding: MoIDX: FDA - Approved KRAS Tests	CGS	KY, OH	KY, OH
	A54200 Billing and Coding: MoIDX: theascreen® KRAS PCR Kit Guidelines			
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54498 Billing and Coding: MoIDX: FDA - Approved KRAS Tests	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
KRAS Tests FDA-Approved				
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54500 Billing and Coding: MoIDX: FDA - Approved KRAS Tests	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A54472 Billing and Coding: MoIDX: FDA - Approved KRAS Tests	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55162 Billing and Coding: MoIDX: FDA - Approved KRAS Tests	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L1CAM Gene Sequencing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54274 Billing and Coding: MoIDX: L1CAM Gene Sequencing Guidelines	CGS	KY, OH	KY, OH
N/A	A55277 Billing and Coding: MoIDX: L1CAM Gene Sequencing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55278 Billing and Coding: MoIDX: L1CAM Gene Sequencing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53659 Billing and Coding: MoIDX: L1CAM Gene Sequencing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55192 Billing and Coding: MoIDX: L1CAM Gene Sequencing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Lynch Syndrome				
L35349 MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	A56882 Billing and Coding: MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	CGS	KY, OH	KY, OH
L36370 MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	A54995 Billing and Coding: MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36374 MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	A54996 Billing and Coding: MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35024 MoIDX: Genetic Testing for Lynch Syndrome Retired 07/03/2022	A54987 Billing and Coding: MoIDX: Genetic Testing for Lynch Syndrome Retired 07/03/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36793 MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	A55135 Billing and Coding: MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L34912 Genetic Testing for Lynch Syndrome	A57450 Billing and Coding: Genetic Testing for Lynch Syndrome	First Coast	FL, PR, VI	FL, PR, VI

LCD	Article	Contractor	Medicare Part A	Medicare Part B
MammaPrint				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54194 Billing and Coding: MoIDX: MammaPrint	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54445 Billing and Coding: MoIDX: MammaPrint	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54447 Billing and Coding: MoIDX: MammaPrint	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53104 Billing and Coding: MoIDX: MammaPrint	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55175 Billing and Coding: MoIDX: MammaPrint®	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
MCOLN1 Genetic Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54277 Billing and Coding: MoIDX: MCOLN1 Genetic Testing Guidelines	CGS	KY, OH	KY, OH
N/A	A55283 Billing and Coding: MoIDX: MCOLN1 Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55284 Billing and Coding: MoIDX: MCOLN1 Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53630 Billing and Coding: MoIDX: MCOLN1 Genetic Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55176 Billing and Coding: MoIDX: MCOLN1 Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
MECP2 Genetic Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54278 Billing and Coding: MoIDX: MECP2 Genetic Testing	CGS	KY, OH	KY, OH
N/A	A55285 Billing and Coding: MoIDX: MECP2 Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55286 Billing and Coding: MoIDX: MECP2 Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53574 Billing and Coding: MoIDX: MECP2 Genetic	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55189 Billing and Coding: MoIDX: MECP2 Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Melanoma Risk Stratification				
L38016 MoIDX: Melanoma Risk Stratification Molecular Testing	A57165 Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing	CGS	KY, OH	KY, OH
L37750 MoIDX: Melanoma Risk Stratification Molecular Testing	A57268 Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37748 MoIDX: Melanoma Risk Stratification Molecular Testing	A57290 Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Melanoma Risk Stratification				
L37725 MoIDX: Melanoma Risk Stratification Molecular Testing	A56961 Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38018 MoIDX: Melanoma Risk Stratification Molecular Testing	A56636 Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
MGMT Promoter Methylation Analysis				
L36113 MoIDX: MGMT Promoter Methylation Analysis	A56983 Billing and Coding: MoIDX: MGMT Promoter Methylation Analysis	CGS	KY, OH	KY, OH
L36188 MoIDX: MGMT Promoter Methylation Analysis	A57432 Billing and Coding: MoIDX: MGMT Promoter Methylation Analysis	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36192 MoIDX: MGMT Promoter Methylation Analysis	A57433 Billing and Coding: MoIDX: MGMT Promoter Methylation Analysis	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35974 MoIDX: MGMT Promoter Methylation Analysis	A56941 Billing and Coding: MoIDX: MGMT Promoter Methylation Analysis	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37001 MoIDX: MGMT Promoter Methylation Analysis	A57577 Billing and Coding: MoIDX: MGMT Promoter Methylation Analysis	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A56106 Billing and Coding: MoIDX: Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A56103 Billing and Coding: MoIDX: Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A56103 Billing and Coding: MoIDX: Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A56072 Billing and Coding: MoIDX: Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors				
L36793 MoIDX: Genetic Testing for Lynch Syndrome Retired 08/20/2022	A56501 Billing and Coding: MoIDX: Microsatellite Instability-High (MSI - H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors Retired 01/26/2023	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Minimal Residual Disease Testing for Cancer (Solid Tumor and Hematologic Cancers)				
L38822 MoIDX: Minimal Residual Disease Testing for Cancer	A58434 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers	CGS	KY, OH	KY, OH
	A58998 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Hematologic Cancers			
L38814 MoIDX: Minimal Residual Disease Testing for Cancer	A58454 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
	A58996 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Hematologic Cancers			
L38816 MoIDX: Minimal Residual Disease Testing for Cancer	A58456 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
	A58997 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Hematologic Cancers			
L38779 MoIDX: Minimal Residual Disease Testing for Cancer	A58376 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
	A58988 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Hematologic Cancers			
L38835 MoIDX: Minimal Residual Disease Testing for Cancer	A58468 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
	A59004 Billing and Coding: MoIDX: Minimal Residual Disease Testing for Hematologic Cancers			
Molecular Assays for the Diagnosis of Cutaneous Melanoma				
L39389 MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	A59163 Billing and Coding: MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	CGS	KY, OH	KY, OH
L39373 MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	A59179 Billing and Coding: MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Molecular Assays for the Diagnosis of Cutaneous Melanoma				
L39375 MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	A59181 Billing and Coding: MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L39345 MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	A59109 Billing and Coding: MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L39479 MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	A59261 Billing and Coding: MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer				
L38997 MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	A58713 Billing and Coding: MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	CGS	KY, OH	KY, OH
Minimal Residual Disease Testing for Cancer (Solid Tumor and Hematologic Cancers)				
L39005 MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	A58718 Billing and Coding: MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L39007 MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	A58724 Billing and Coding: MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38985 MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	A58700 Billing and Coding: MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L39042 MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	A58759 Billing and Coding: MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia				
L39276 MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	A59051 Billing and Coding: MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	CGS	KY, OH	KY, OH
L39262 MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	A59032 Billing and Coding: MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia				
L39264 MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	A59034 Billing and Coding: MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L39256 MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	A59015 Billing and Coding: MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L39356 MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	A59121 Billing and Coding: MoIDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
myPath Melanoma Assay				
L37907 MoIDX: myPath Melanoma Assay Retired 08/06/2023	A56878 Billing and Coding: MoIDX: myPath® Melanoma Assay Retired 08/06/2023	CGS	KY, OH	KY, OH
L37879 MoIDX: myPath® Melanoma Assay Retired 08/06/2023	A57626 Billing and Coding: MoIDX: myPath® Melanoma Assay Retired 08/06/2023	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L37881 MoIDX: myPath® Melanoma Assay Retired 08/06/2023	A57627 Billing and Coding: MoIDX: myPath® Melanoma Assay Retired 08/06/2023	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L37859 MoIDX: myPath® Melanoma Assay Retired 08/06/2023	A56858 Billing and Coding: MoIDX: myPath® Melanoma Assay Retired 08/06/2023	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37923 MoIDX: myPath® Melanoma Assay Retired 08/12/2023	A57580 Billing and Coding: MoIDX: myPath® Melanoma Assay Retired 08/12/2023	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Neuroendocrine Tumors/Neoplasms				
L37851 Biomarker Testing for Neuroendocrine Tumors/Neoplasms	A57059 Billing and Coding: Biomarker Testing for Neuroendocrine Tumors/Neoplasms	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI
Next-Generation Sequencing for Myeloid Malignancies and Suspected Myeloid Malignancies				
L38070 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	A57873 Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	CGS	KY, OH	KY, OH

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Next-Generation Sequencing for Myeloid Malignancies and Suspected Myeloid Malignancies				
L38123 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	A57891 Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38125 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	A57892 Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38047 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	A57837 Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38176 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	A57878 Billing and Coding: MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Next-Generation Sequencing for Myeloid Malignancies and Suspected Myeloid Malignancies				
L37606 Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases	A56793 Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI
Next-Generation Sequencing for Solid Tumors				
L38067 MoIDX: Next-Generation Sequencing for Solid Tumors	A57870 Billing and Coding: MoIDX: Next-Generation Sequencing for Solid Tumors	CGS	KY, OH	KY, OH
L38119 MoIDX: Next-Generation Sequencing for Solid Tumors	A57901 Billing and Coding: MoIDX: Next-Generation Sequencing for Solid Tumors	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38121 MoIDX: Next-Generation Sequencing for Solid Tumors	A57905 Billing and Coding: MoIDX: Next-Generation Sequencing for Solid Tumors	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38045 MoIDX: Next-Generation Sequencing for Solid Tumors	A57831 Billing and Coding: MoIDX: Next-Generation Sequencing for Solid Tumors	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38158 MoIDX: Next-Generation Sequencing for Solid Tumors	A57858 Billing and Coding: MoIDX: Next-Generation Sequencing for Solid Tumors	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L37810 Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms	A56867 Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Next-Generation Sequencing Testing in Cancer – Targeted and Comprehensive Genomic Profile				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54901 Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next Generation Sequencing Testing in Cancer	CGS	KY, OH	KY, OH
L38119 MoIDX: Next-Generation Sequencing for Solid Tumors	A55624 Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38123 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies				
L38121 MoIDX: Next-Generation Sequencing for Solid Tumors	A56518 Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38125 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies				
L38045 MoIDX: Next-Generation Sequencing for Solid Tumors	A54795 Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38047 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies				
L38158 MoIDX: Next-Generation Sequencing for Solid Tumors	A55197 Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Next Generation Sequencing Testing in Cancer	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
L38176 MoIDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies				
NRAS Genetic Testing				
L35442 MoIDX: NRAS Genetic Testing	A56998 Billing and Coding: MoIDX: NRAS Genetic Testing	CGS	KY, OH	KY, OH
L36335 MoIDX: NRAS Genetic Testing	A57486 Billing and Coding: MoIDX: NRAS Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36339 MoIDX: NRAS Genetic Testing	A57487 Billing and Coding: MoIDX: NRAS Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35073 MoIDX: NRAS Genetic Testing	A56962 Billing and Coding: MoIDX: NRAS Genetic Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36797 MoIDX: NRAS Genetic Testing	A57581 Billing and Coding: MoIDX: NRAS Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Oncotype DX® Breast Cancer Assay				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54195 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer Assay	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54480 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer Assay	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54482 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer Assay	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53105 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer Assay	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55230 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer Assay	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Oncotype DX® Breast Cancer for DCIS Genomic Health™				
L36951 MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	A56887 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	CGS	KY, OH	KY, OH
L36941 MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	A57619 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36947 MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	A57620 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L36912 MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	A56870 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L37199 MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	A57583 Billing and Coding: MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Oncotype DX® Colon Cancer Assay				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54196 Billing and Coding: MoIDX: Oncotype DX® Colon Cancer Assay Update	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54484 Billing and Coding: MoIDX: Oncotype DX® Colon Cancer	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54486 Billing and Coding: MoIDX: Oncotype DX® Colon Cancer	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53106 MoIDX: Oncotype DX® Colon Cancer Assay Update	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55231 Billing and Coding: MoIDX: Oncotype DX® Colon Cancer Assay Update	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Oncotype DX® Prostate Cancer Assay/Prostate Score				
N/A	A56372 Billing and Coding: MoIDX: Oncotype DX® Genomic Prostate Score	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
Ovarian Cancer Testing				
L38371 Multimarker Serum Tests Related to Ovarian Cancer Testing	A57020 Billing and Coding: Multimarker Serum Tests Related to Ovarian Cancer Testing	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI
Pigmented Lesion Assay				
L38111 MoIDX: Pigmented Lesion Assay	A57915 Billing and Coding: MoIDX: Pigmented Lesion Assay	CGS	KY, OH	KY, OH
L38151 MoIDX: Pigmented Lesion Assay	A58052 Billing and Coding: MoIDX: Pigmented Lesion Assay	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38153 MoIDX: Pigmented Lesion Assay	A58053 Billing and Coding: MoIDX: Pigmented Lesion Assay	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38051 MoIDX: Pigmented Lesion Assay	A57868 Billing and Coding: MoIDX: Pigmented Lesion Assay	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38178 MoIDX: Pigmented Lesion Assay	A57983 Billing and Coding: MoIDX: Pigmented Lesion Assay	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
PIK3CA Gene Tests				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54295 Billing and Coding: MoIDX: PIK3CA Gene Tests	CGS	KY, OH	KY, OH
N/A	A55597 Billing and Coding: MoIDX: PIK3CA Gene Tests	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55602 Billing and Coding: MoIDX: PIK3CA Gene Tests	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53558 Billing and Coding: MoIDX: PIK3CA Gene Tests	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55200 Billing and Coding: MoIDX: PIK3CA Gene Tests	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Plasma-Based Genomic Profiling in Solid Tumors				
L38065 MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	A57917 Billing and Coding: MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	CGS	KY, OH	KY, OH
L39230 MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	A58973 Billing and Coding: MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L39232 MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	A58975 Billing and Coding: MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38043 MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	A57867 Billing and Coding: MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38168 MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	A57936 Billing and Coding: MoIDX: Plasma-Based Genomic Profiling in Solid Tumors	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer				
L38284 MoIDX: Predictive Classifiers for Early Stage Non-small Cell Lung Cancer	A58038 Billing and Coding: MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	CGS	KY, OH	KY, OH
L38327 MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	A57329 Billing and Coding: MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38329 MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	A57330 Billing and Coding: MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38238 MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	A58031 Billing and Coding: MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38443 MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	A57112 Billing and Coding: MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
PreDx®				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54296 Billing and Coding: MoIDX: PreDx® Retired 06/15/2022	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A55594 Billing and Coding: MoIDX: PreDx® Retired 01/01/2023	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A55599 Billing and Coding: MoIDX: PreDx® Retired 01/01/2023	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53489 Billing and Coding: MoIDX: PreDx® Retired 06/15/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55201 Billing and Coding: MoIDX: PreDx® Retired 02/23/2023	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
ProgenSA® PCA3 Assay				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54197 Billing and Coding: MoIDX: ProgenSA® PCA3 Assay Coverage Update	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54489 Billing and Coding: MoIDX: ProgenSA® PCA3 Assay Retired 08/08/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54492 Billing and Coding: MoIDX: ProgenSA® PCA3 Assay Retired 08/08/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53107 Billing and Coding: MoIDX: ProgenSA® PCA3 Assay Coverage Update Retired 07/03/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Progensa® PCA3 Assay				
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55202 Billing and Coding: MoIDX: Progensa® PCA3 Assay Coverage Update Retired 07/02/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Prognostic and Predictive Molecular Classifiers for Bladder Cancer				
L38586 MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	A58065 Billing and Coding: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	CGS	KY, OH	KY, OH
L38647 MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	A58181 Billing and Coding: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38649 MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	A58187 Billing and Coding: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38576 MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	A58028 Billing and Coding: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38684 MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	A58211 Billing and Coding: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Prostate Cancer Detection with IsoPSA®				
L39284 Prostate Cancer Detection with IsoPSA®	A59066 Billing and Coding: Prostate Cancer Detection with IsoPSA™	CGS	KY, OH	KY, OH
Prostate Cancer Genomic Classifier Assay for Men with Localized Disease				
L38303 MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	A58371 Billing and Coding: MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	CGS	KY, OH	KY, OH
L38339 MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	A57372 Billing and Coding: MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38341 MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	A57236 Billing and Coding: MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38292 MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	A58343 Billing and Coding: MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38433 MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	A57106 Billing and Coding: MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Repeat Germline Testing				
L38288 MoIDX: Repeat Germline Testing	A57141 Billing and Coding: MoIDX: Repeat Germline Testing	CGS	KY, OH	KY, OH
L38351 MoIDX: Repeat Germline Testing	A57331 Billing and Coding: MoIDX: Repeat Germline Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L38353 MoIDX: Repeat Germline Testing	A57332 Billing and Coding: MoIDX: Repeat Germline Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L38274 MoIDX: Repeat Germline Testing	A58017 Billing and Coding: MoIDX: Repeat Germline Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L38429 MoIDX: Repeat Germline Testing	A57100 Billing and Coding: MoIDX: Repeat Germline Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
ResponseDX Tissue of Origin®				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54198 Billing and Coding: MoIDX: ResponseDX Tissue of Origin®	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A54494 Billing and Coding: MoIDX: ResponseDX Tissue of Origin®	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A54496 Billing and Coding: MoIDX: ResponseDX Tissue of Origin®	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53108 Billing and Coding: MoIDX: ResponseDX Tissue of Origin®	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55204 Billing and Coding: MoIDX: ResponseDX Tissue of Origin®	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
SEPT9 Gene Test				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54300 Billing and Coding: MoIDX: SEPT9 Gene Test	CGS	KY, OH	KY, OH
N/A	A55623 Billing and Coding: MoIDX: SEPT9 Gene Test	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55628 Billing and Coding: MoIDX: SEPT9 Gene Test	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53702 Billing and Coding: MoIDX: SEPT9 Gene Test	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55206 Billing and Coding: MoIDX: SEPT9 Gene Test	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Short Tandem Repeat STR Markers and Chimerism				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54830 Billing and Coding: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268)	CGS	KY, OH	KY, OH
N/A	A57842 Billing and Coding: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268)	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
Short Tandem Repeat STR Markers and Chimerism				
N/A	A57843 Billing and Coding: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268)	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A54832 Billing and Coding: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268)	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55621 Billing and Coding: MoIDX: Short Tandem Repeat (STR) Markers and Chimerism codes 81265-81268	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
SMPD1 Genetic Testing				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54285 Billing and Coding: MoIDX: SMPD1 Genetic Testing	CGS	KY, OH	KY, OH
N/A	A55627 Billing and Coding: MoIDX: SMPD1 Genetic Testing	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
N/A	A55631 Billing and Coding: MoIDX: SMPD1 Genetic Testing	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
N/A	A53624 Billing and Coding: MoIDX: SMPD1 Genetic Testing	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55208 Billing and Coding: MoIDX: SMPD1 Genetic Testing	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer				
N/A	A55851 Billing and Coding: MoIDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer Retired 10/27/2022	CGS	KY, OH	KY, OH
L35160 MoIDX: Molecular Diagnostic Tests (MDT)	A55881 Billing and Coding: MoIDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer Retired 10/27/2022	Noridian	AS, CA, GU, HI, MP, NV	AS, CA, GU, HI, MP, NV
L36256 MoIDX: Molecular Diagnostic Tests (MDT)	A55888 Billing and Coding: MoIDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer Retired 10/27/2022	Noridian	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A55822 Billing and Coding: MoIDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer Retired 10/27/2022	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV

LCD	Article	Contractor	Medicare Part A	Medicare Part B
ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer				
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55846 Billing and Coding: MoIDX: ThermoFisher Oncomine™ Dx Target Test For Non-Small Cell Lung Cancer Retired 10/27/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE
Thyroid Nodule Molecular Testing				
L38968 Thyroid Nodule Molecular Testing	A58656 Billing and Coding: Thyroid Nodule Molecular Testing	NGS	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI
Vectra™ DA				
L36021 MoIDX: Molecular Diagnostic Tests (MDT)	A54201 Billing and Coding: MoIDX: Vectra™ DA Retired 02/11/2022	CGS	KY, OH	KY, OH
L35025 MoIDX: Molecular Diagnostic Tests (MDT)	A53110 Billing and Coding: Lab: Vectra™ DA Retired 06/07/2023	Palmetto	AL, GA, NC, SC, TN, VA, WV	AL, GA, NC, SC, TN, VA, WV
L36807 MoIDX: Molecular Diagnostic Tests (MDT)	A55223 Billing and Coding: MoIDX: Vectra™ DA Retired 02/24/2022	WPS	IA, IN, KS, MI, MO, NE	IA, IN, KS, MI, MO, NE

CMS Benefit Policy Manual

[Chapter 15; § 80.1–80.1.3 Clinical Laboratory Services](#)

CMS Claims Processing Manual

[Chapter 12; § 60 Payment for Pathology Services](#)

[Chapter 16, § 10.2 General Explanation of Payment; § 20 Calculation of Payment Rates - Clinical Laboratory Test Fee Schedules; § 40 Billing for Clinical Laboratory Tests](#)

CMS Transmittals

[Transmittal 2439, Change Request 11655, Dated 02/21/2020 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--July 2020 Update\)](#)

[Transmittal 4481, Change Request 11574, Dated 12/20/2019 \(Internet Only Manual Update to Pub 100-04, Chapter 16, Section 40.8 – Laboratory Date of Service Policy\)](#)

[Transmittal 10092, Change Request 11749, Dated 05/01/2020 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--October 2020 Update\)](#)

[Transmittal 10193, Change Request 11655, Dated 06/19/2020 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--July 2020 Update\)](#)

[Transmittal 10261, Change Request 11905, Dated 07/31/2020 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--January 2021 Update\)](#)

[Transmittal 10346, Change Request 11837, Dated 09/11/2020 \(National Coverage Determination \(NCD 90.2\): Next Generation Sequencing \(NGS\) for Medicare Beneficiaries with Germline \(Inherited\) Cancer\)](#)

[Transmittal 10624, Change Request 12124, Dated 03/23/2021 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--July 2021\)](#)

[Transmittal 11055, Change Request 12483, Dated 10/21/2021 \(National Coverage Determination \(NCD\) 90.2, Next Generation Sequencing \(NGS\)\)](#)

[Transmittal 11400, Change Request 12705, Dated 05/04/2022 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--October 2022 Update\)](#)

[Transmittal 11460, Change Request 12705, Dated 06/17/2022 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determination \(NCDs\)--October 2022 Update\)](#)

[Transmittal 11461, Change Request 12483, Dated 06/21/2022 \(National Coverage Determination \(NCD\) 90.2, Next Generation Sequencing \(NGS\)\)](#)

[Transmittal 12184, Change Request 13278, Dated 08/03/2023, \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determinations \(NCDs\)--January 2024 Update\)](#)

[Transmittal 12319, Change Request 13391, Dated 10/19/2023 \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determinations \(NCDs\)--April 2024 Update--CR 2 of 2](#)
[Transmittal 12350, Change Request 13391, Dated 11/03/2023, \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determinations \(NCDs\)-- April 2024 Update--CR 2 of 2\)](#)
[Transmittal 12355, Change Request 13278, Dated 11/09/2023, \(International Classification of Diseases, 10th Revision \(ICD-10\) and Other Coding Revisions to National Coverage Determinations \(NCDs\)-- January 2024 Update\)](#)

Others

[CMS Clinical Laboratory Fee Schedule, CMS Website](#)
[Palmetto GBA MoIDx Website](#)
[Palmetto GBA MoIDx Manual, Palmetto GBA MoIDx Website](#)
[PreDx® Coding and Billing Guidelines \(CM00040\), CGS Website](#)

Guideline History/Revision Information

Revisions to this summary document do not in any way modify the requirement that services be provided and documented in accordance with the Medicare guidelines in effect on the date of service in question.

Date	Summary of Changes
08/01/2024	<p>Related Policies</p> <ul style="list-style-type: none"> • Updated reference link for the Medicare Advantage Medical Policies titled: <ul style="list-style-type: none"> ○ <i>Clinical Diagnostic Laboratory Services</i> ○ <i>Pharmacogenomics Testing</i> • Updated reference link to reflect the current policy title for <i>Urogenital/Anogenital (UG/AG) Panels</i>
04/10/2024	<p>Applicable Codes Non-Covered Diagnosis Codes</p> <ul style="list-style-type: none"> • Added Z02.84 <p>Administrative</p> <ul style="list-style-type: none"> • Archived previous policy version MPG210.28

Purpose

The Medicare Advantage Policy Guideline documents are generally used to support UnitedHealthcare Medicare Advantage claims processing activities and facilitate providers' submission of accurate claims for the specified services.

The document can be used as a guide to help determine applicable:

- Medicare coding or billing requirements, and/or
- Medical necessity coverage guidelines; including documentation requirements.

UnitedHealthcare follows Medicare guidelines such as NCDs, LCDs, LCAs, and other Medicare manuals for the purposes of determining coverage. It is expected providers retain or have access to appropriate documentation when requested to support coverage. Please utilize the links in the [References](#) section above to view the Medicare source materials used to develop this resource document. This document is not a replacement for the Medicare source materials that outline Medicare coverage requirements. Where there is a conflict between this document and Medicare source materials, the Medicare source materials will apply.

Terms and Conditions

The Medicare Advantage Policy Guidelines are applicable to UnitedHealthcare Medicare Advantage Plans offered by UnitedHealthcare and its affiliates.

These Policy Guidelines are provided for informational purposes, and do not constitute medical advice. Treating physicians and healthcare providers are solely responsible for determining what care to provide to their patients. Members should always consult their physician before making any decisions about medical care.

Benefit coverage for health services is determined by the member specific benefit plan document* and applicable laws that may require coverage for a specific service. The member specific benefit plan document identifies which services are covered, which are excluded, and which are subject to limitations. In the event of a conflict, the member specific benefit plan document supersedes the Medicare Advantage Policy Guidelines.

Medicare Advantage Policy Guidelines are developed as needed, are regularly reviewed and updated, and are subject to change. They represent a portion of the resources used to support UnitedHealthcare coverage decision making. UnitedHealthcare may modify these Policy Guidelines at any time by publishing a new version of the policy on this website. Medicare source materials used to develop these guidelines include, but are not limited to, CMS National Coverage Determinations NCDs, Local Coverage Determinations LCDs, Medicare Benefit Policy Manual, Medicare Claims Processing Manual, Medicare Program Integrity Manual, Medicare Managed Care Manual, etc. The information presented in the Medicare Advantage Policy Guidelines is believed to be accurate and current as of the date of publication and is provided on an "AS IS" basis. Where there is a conflict between this document and Medicare source materials, the Medicare source materials will apply.

You are responsible for submission of accurate claims. Medicare Advantage Policy Guidelines are intended to ensure that coverage decisions are made accurately based on the code or codes that correctly describe the health care services provided. UnitedHealthcare Medicare Advantage Policy Guidelines use Current Procedural Terminology CPT®, Centers for Medicare and Medicaid Services CMS, or other coding guidelines. References to CPT® or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee claims payment.

Medicare Advantage Policy Guidelines are the property of UnitedHealthcare. Unauthorized copying, use, and distribution of this information are strictly prohibited.

*For more information on a specific member's benefit coverage, please call the customer service number on the back of the member ID card or refer to the [Administrative Guide](#).